View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill

Coffee, Croissants & Credit/AT&T, Amazon, Merlin Properties

Telecom - AT&T celebrates first phone call with repackaged investment message

 PRESS RELEASE

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Marke...

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat...

David Barden ... (+2)
  • David Barden
  • Vikash Harlalka

Broadband cNPS comparisons by tech & operator - The latest data availa...

Scouring the data in this report, we’d point you to the appendix for a quick review. What stands out is that when a broadband customer interacts with a sales rep, presumably they are doing so with a problem or request that an automated or AI-driven IVR cannot address. Almost without fail, sales rep interactions are the Achilles heal of the market right now and likely a core reason, care scores suffer. The operator that can solve this puzzle, and it could be cable, has a window to shift their rel...

 PRESS RELEASE

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results a...

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a...

 PRESS RELEASE

Lifecore Biomedical to Report Financial Results for the Fourth Quarter...

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026 Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time t...

 PRESS RELEASE

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Pr...

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

VPG to Present at Investor Conferences in March 2026

VPG to Present at Investor Conferences in March 2026 CHESTERBROOK, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will present at the following investor conferences in March 2026: March 18-19, 2026. Sidoti Virtual Conference. The company’s presentation is scheduled to begin at 10:00am ET on Thursday, March 19, 2026. A live and on-demand webcast of VPG’s presentation will be available to the public and can be accessed from the following link: , or on VPG’s website: . For more information, or for...

David Barden ... (+2)
  • David Barden
  • Vikash Harlalka

Broadband Spring 2026 – A fine time for FWA

In this Broadband Spring report, we share a quick update on broadband industry trends from 4Q25 heading into 2026E. Industry net adds improved meaningfully in 4Q25 from a year ago but remained slightly below last year when we adjust for the loss of ACP. Net adds for the quarter were in line with the pre-pandemic norm but trailing twelve-month net adds remain below pre-pandemic levels. We take a deep-dive here into FWA’s continued strong momentum, by carrier, and how it fits into the overall broa...

 PRESS RELEASE

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovat...

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s D...

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Poten...

 PRESS RELEASE

OPKO Health to Participate in the Jefferies Biotech on the Beach Summi...

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...

 PRESS RELEASE

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...

Blair Levin
  • Blair Levin

C-Band Update: What Does the El Paso Airport Shutdown and Broadcaster ...

The El Paso Airport Shutdown does not on the surface reference FCC spectrum policy. But what happened is a tale of two agencies, that both rhymes with past conflicts between the FCC and FAA and raises questions about the wireless industry’s hope for access to the Upper C-Band. In this note, we address those questions and others raised by broadcasters seeking to limit the amount of spectrum that wireless can bid on in the upcoming C-Band auction.

David Barden
  • David Barden

That’s a wrap! Takeaways from Metro Connect day 2

We just wrapped up day 2 at Metro Connect where we had meetings with a number of additional fiber operators. In this short note, we share our incremental takeaways from conversations at the event.

 PRESS RELEASE

WillScot Announces Nationwide Expansion of Fencing Solutions

WillScot Announces Nationwide Expansion of Fencing Solutions SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- WillScot (Nasdaq: WSC), the industry leader in modular building and storage solutions, today announced that its fencing and perimeter‑security offering is now available nationwide, marking a significant milestone for the Company and reflecting the rapid scale‑up of RentaFence.com across the U.S. “Expanding our fencing offering nationally strengthens our ability to support customers from the very start of their projects,” said Tim Boswell, President and Chief Executive Officer...

American Assets Trust Inc: 1 director

A director at American Assets Trust Inc bought 82,386 shares at 19.417USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch